The HDAC1 Knockout T-47D Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the T-47D human breast cancer cell line, engineered for targeted disruption of the HDAC1 gene. This polyclonal knockout model provides a loss-of-function system for studying HDAC1-dependent epigenetic regulation, transcriptional control, and tumor biology without the complexities of clonal selection.
The T-47D cell line is a well-characterized hormone-responsive breast cancer model, originating from the pleural effusion of an invasive ductal carcinoma. These epithelial cells are extensively employed to investigate estrogen receptor signaling, hormone-dependent proliferation, and endocrine therapy responses, making them a highly relevant host for breast cancer research and drug discovery.
HDAC1 encodes a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histone H3 and H4, as well as non-histone substrates including p53, E2F1, estrogen receptor ??, NF-??B, tubulin, and HSP90. This deacetylation activity generally promotes chromatin compaction and transcriptional repression. HDAC1 functions within multi-protein complexes such as Sin3A and NuRD (comprising MTA1/2, RbAp46/48, and MBD3), and interacts with CoREST, LSD1, and the retinoblastoma protein Rb. Its activity is regulated by phosphorylation via casein kinase II and protein kinase A, while upstream transcription factors E2F, p53, Sp1, and Myc modulate its expression. Downstream effects include altered expression of cyclin D1, p21, Bax, and Bcl-2, thereby governing cell cycle progression, apoptosis, and differentiation.
In breast cancer, aberrant HDAC1 activity contributes to tumorigenesis by dysregulating gene expression patterns, evading apoptosis, and modulating hormone responsiveness. Disruption of HDAC1 in the T-47D background enables dissection of its roles in estrogen receptor-mediated transcription, chromatin remodeling, and cell cycle control. This polyclonal knockout population is particularly valuable for assessing the impact of HDAC1 loss on hormone-driven proliferation and for modeling context-dependent effects of HDAC inhibition in an epithelial breast cancer milieu.
Typical research applications include epigenetic regulation studies, chromatin dynamics analysis using chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) for histone acetylation marks, and western blotting to assess HDAC1 and acetylated protein levels. Researchers utilize this model for drug target validation with HDAC inhibitors (e.g., SAHA, TSA), apoptosis and cell cycle flow cytometry, colony formation, and migration/invasion assays. It also supports investigation of crosstalk between HDAC1 and pathways such as p53/p21 and Wnt/??-catenin. For further details or technical support, please contact Ascent Research.
